Narco-Terrorism Today: the Role of Fenethylline and Tramadol

Total Page:16

File Type:pdf, Size:1020Kb

Narco-Terrorism Today: the Role of Fenethylline and Tramadol Narco-terrorism today: the role of fenethylline and tramadol Introduction The relationship between psychoactive substances and violent crimes such as war acts and terrorism dates long back in history. Viking warriors famously fought in a trance-like state, probably as a result of taking agaric "magic" mushrooms and bog myrtle (McCarthy, 2016). More recently, under the German Nazis’ Third Reich, methamphetamine gained an extreme popularity, despite an official “drug-free” propaganda. Under the trademark Pervitin, it could be sold without prescription until 1939, and it was not regulated by the Reich Opium Law of 1941. Pervitin was commonly used in recreational and working settings, and, of course, the stimulant was shipped to German soldiers when the troops invaded France, allowing them to march sleepless for 36 to 50 hours (Ohler, 2016). On the other side, Benzedrine, a racemic mixture of amphetamine initially developed as a bronchodilator, was the stimulant of choice of the Allied forces during World War II (McCarthy, 2016). Vietnam War (1955-1975) is considered to be the first “pharmacological war” of modern history, so called due to an unprecedented high level of consumption of psychoactive substances by military personnel (Kamienski, 2016). In 1971, a report by the House Select Committee on Crime revealed that from 1966 to 1969, the US armed forces had used 225 million tablets of stimulants, mostly Dexedrine (dextroamphetamine), an amphetamine derivative that is nearly twice as strong as the Benzedrine used in the Second World War (Kamienski, 2016). The use of illicit drugs such as stimulants or painkillers by terrorists or insurgents while undertaking their terrorist activities has been hypothesized but still needs further documentation. Moreover, besides being fuelled by psychoactive drugs, terrorism also needs to be funded, and drug trafficking makes a very profitable and secure business (EMCDDA, 2016). The Revolutionary Armed Forces of Colombia, known as FARC, is Latin America’s oldest guerrilla group: since the 1980s, it has been taxing cocaine producers and smugglers in rebel-controlled areas in order to finance their activities (Otis, 2014). In Afghanistan’s poppy-rich southern and southwestern regions, Taliban profit from opium traffickers who operate along the Pakistan border (Peters, 2009). The recent development of online drug markets in both surface and deep Web may also provide a further and safer opportunity for buying and selling psychoactive products (Orsolini et al., 2017). Chemical, pharmacological and metabolic characteristics Fenethylline Fenethylline, also spelled phenethylline or fenetylline, is a co-drug of amphetamine and theophylline. In the fenetylline molecule, theophylline is covalently linked with amphetamine via an alkyl chain; the drug exhibits effects qualitatively and quantitatively different from those of parent compounds, strongly suggesting that the compound exerts its own intrinsic activity (Nickel et al., 1986) (Fig.1). Fenethylline was originally synthesized by the German company Degussa AG in 1961 as part of an investigational program on theophylline derivatives, with an interest on its effects on cardiovascular, pulmonary and central nervous systems. One of the main advantages of fenethylline over other amphetamines is that it does not increase significantly blood pressure, so it can be used by patients suffering from cardiovascular conditions (Kikura and Nakahara, 1997). Fig.1 Chemical structure of fenethylline Source: https://pubchem.ncbi.nlm.nih.gov/compound/fenethylline#section=2D-Structure Fenethylline is a crystal solid with the molecular formula C18H23N5O2, and it is usually found as its hydrochloric salt (1892-80-4,cas lookchem). According to Yoshimura, who investigated the metabolism of fenethylline in male rats and in three male volunteers, six metabolites have been identified, and the two major are carboxymethyl theophylline and amphetamine (Yoshimura et al., 1988). The 13.7% and 24.5% of an oral dose is apparently cleaved metabolically in human beings into theophylline (weak stimulant, pharmacologically related to caffeine) and amphetamine (active stimulant), respectively (Shulgin, 1975; Kraemer and Maurer, 2002). Fenethylline was primarily proposed in the 1960s as a treatment for children with a diagnosis of attention deficit hyperactivity disorder, narcolepsy and depression. It was marketed under the brand names Captagon, Biocapton, and Fitton, initially as a non- prescription psychostimulant, but later on it could only be prescribed under medical supervision (Kristen, Schaefer and von Schlichtegroll, 1986). Fenethylline was never approved by the US Food and Drug Administration: it was later listed as a “Schedule I controlled” substance in the United States, and became illegal in most countries in 1986 (UNODC, 2014). Tramadol Tramadol is a central analgesic with low affinity for opioid receptors, structurally related to codeine and morphine (Grond and Sablotzki, 2004). It was first synthesized in 1962 by Grünenthal GmbH in Germany, and it exists as a racemic mixture of the right and left enantiomers (World Health Organization, 2014) (fig.2). In its hydrochloride form, it appears as a white crystalline powder with a bitter taste, and it is easily soluble in both water and methanol. The analgesic mechanism of action of tramadol includes both non- opioid components, (e.g., noradrenergic and serotonergic components, due to the effects of right and left enantiomers on neurotransmitters’ reuptake), and opioid components (due to the binding of the O-desmethyl metabolite to the µ receptors (Scott and Perry, 2000; Raffa et al., 2012). The fact that non-opioid mechanisms are involved in its analgesic effect is supported by the observation that naloxone only partially antagonizes tramadol-induced analgesia (World Health Organization, 2014). In conclusion, the analgesic effect of tramadol appears to be produced by a multimodal mechanism involving the μ-opioid system, the noradrenergic system, and the serotonergic system. Tramadol acts as a releaser and reuptake inhibitor of serotonin, and as a reuptake inhibitor of noradrenaline, and its metabolite is active as a μ-opioid receptor agonist. Noradrenaline and serotonin have long been considered to be involved in the regulation of nociceptive perceptions, and tramadol has been the first pharmacological product to employ this unique mechanism of action. Fig.2 Chemical structure of tramadol Source: https://pubchem.ncbi.nlm.nih.gov/compound/63013#section=2D-Structure Tramadol was initially approved for medical use in Germany in 1977, although it was not approved by the Food and Drugs Administration (FDA) until 1995. Tramadol has a potency similar to that of codeine, and its bioavailability is approximately 20% of oral morphine (Grond and Sablotzki, 2004). The efficacy and safety of tramadol in treating both acute and chronic moderate to severe pain has been demonstrated in extensive clinical studies. Tramadol has also shown efficacy as a treatment option for neuropathic pain, in which usually opioid drugs have limited effect; a further advantage of tramadol with respect to conventional opioids is that it presents less withdrawal symptoms and a lower risk for respiratory depression (Bravo, Mico and Berrocoso, 2017). Tramadol is marketed in a variety of pharmacological formulations (oral, sublingual, rectal, intravenous, intramuscular), and immediate- and extended-release versions are available too. The daily dose of the drug should not exceed 400 mg: most treatments range between 100 and 400 mg (Tramadol Uses, Side Effects, Dosage & Warnings - Drugs.com, 2017). Tramadol is listed as a prescription-only drug in most countries. It is under control in Bahrein, Mauritius, Australia, Iran, Sweden, Venezuela, Ukraine, Egypt Jordan, Saudi Arabia and the UK (World Health Organization, 2014). Misuse, toxicology and fatalities Fenethylline For low dosages, fenethylline adverse reactions are commonly limited to minor sympathomimetic effects (vertigo, dry mouth, palpitations) (Kristen, Schaefer and von Schlichtegroll, 1986). Higher fenethylline consumption has been linked to potential cardiac and vascular toxic effects (e.g., haemorrhagic central retina vein occlusion, acute myocardial infarction, acute heart failure) (Al-Ghadyan, Rushood and Alhumeidan, 2009; Ulucay, Arpacik and Aksoy, 2012; Elasfar, Eldein-Ahmad and Alsagha, 2014). With respect to psychiatric adverse consequences, the potential development of fenethylline- induced psychosis, presenting with symptoms such as aggression, agitation and paranoid delusions, is reported (Shufman and Dickman, 1999; Twark and Suzuki, 2016). Drug discontinuation usually determines a quick resolution of the symptomatology, but in some cases antipsychotic medications (e.g., haloperidol, olanzapine) may be needed (Leelahanaj, Kongsakon and Netrakom, 2005). Amphetamine-induced psychosis may be very similar in its clinical features to schizophrenia spectrum psychosis, and therefore it may be difficult for clinicians to distinguish the two in an acute setting. More pronounced grandiosity and visual hallucinations, together with a faster, although often incomplete, recovery, are considered to be more typical of induced psychosis with respect to schizophrenic psychosis; nevertheless, the two conditions share several susceptibility genes, suggesting a common vulnerability pathway (Bramness et al., 2012). Fenethylline appears to be a major substance of misuse in the Middle East, where it is most known under
Recommended publications
  • Theophylline Level
    Lab Dept: Chemistry Test Name: THEOPHYLLINE LEVEL General Information Lab Order Codes: THEM Synonyms: Aminophylline, Theo-Dur, Slo-Bid CPT Codes: 80198 - Theophylline Test Includes: Theophylline concentration reported in mcg/mL. Logistics Test indications: Assessing and adjusting theophylline dosage for optimal therapeutic level. Assessing theophylline toxicity Theophylline is used to relax smooth muscles of the bronchial airways and pulmonary blood vessels to relieve and prevent symptoms of asthma and bronchospasm. Caffeine is a minor metabolite and is often seen in neonates taking theophylline. Peak levels are achieved in 30–90 minutes depending on the compound and type of preparation. Theophylline has a half-life of approximately 4 hours in children and adult smokers, and 8.7 hours in nonsmoking adults. Lab Testing Sections: Chemistry Referred to: Mayo Clinic Laboratories (MML Test: THEO) Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: Monday - Saturday Turnaround Time: 1 day Special Instructions: N/A Specimen Specimen Type: Blood Container: Preferred: Serum Gel (SST) Alternate: Red Top Draw Volume: 1.5 mL blood Processed Volume: 0.5 mL (Minimum: 0.25 mL) serum Collection: Routine blood collection Special Processing: Lab Staff: Centrifuge specimen within 2 hours of collection. Store and ship at refrigerated temperature. Patient Preparation: None Sample Rejection: Mislabeled or unlabeled specimen; gross hemolysis Interpretive Reference Range: Therapeutic: Bronchodilation: 8.0-20.0 mcg/mL Neonatal apnea (< or =4 weeks old): 6.0-13.0 mcg/mL Interpretation: Response to theophylline is directly proportional to the serum level. Patients usually receive the best response when the serum level is above 8.0 mcg/mL, with minimal toxicity experienced as long as the level is less than or equal to 20.0 mcg/mL Critical Values: >20.0 mcg/mL Limitations: Coadministration of cimetidine and erythromycin will significantly inhibit theophylline clearance, requiring dosagereduction.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Synthetic Cathinones ("Bath Salts")
    Synthetic Cathinones ("Bath Salts") What are synthetic cathinones? Synthetic cathinones, more commonly known as "bath salts," are synthetic (human- made) drugs chemically related to cathinone, a stimulant found in the khat plant. Khat is a shrub grown in East Africa and southern Arabia, and people sometimes chew its leaves for their mild stimulant effects. Synthetic variants of cathinone can be much stronger than the natural product and, in some cases, very dangerous (Baumann, 2014). In Name Only Synthetic cathinone products Synthetic cathinones are marketed as cheap marketed as "bath salts" should substitutes for other stimulants such as not be confused with products methamphetamine and cocaine, and products such as Epsom salts that people sold as Molly (MDMA) often contain synthetic use during bathing. These cathinones instead (s ee "Synthetic Cathinones bathing products have no mind- and Molly" on page 3). altering ingredients. Synthetic cathinones usually take the form of a white or brown crystal-like powder and are sold in small plastic or foil packages labeled "not for human consumption." Also sometimes labeled as "plant food," "jewelry cleaner," or "phone screen cleaner," people can buy them online and in drug paraphernalia stores under a variety of brand names, which include: Flakka Bloom Cloud Nine Lunar Wave Vanilla Sky White Lightning Scarface Image courtesy of www.dea.gov/pr/multimedia- library/image-gallery/bath-salts/bath-salts04.jpg Synthetic Cathinones • January 2016 • Page 1 How do people use synthetic cathinones? People typically swallow, snort, smoke, or inject synthetic cathinones. How do synthetic cathinones affect the brain? Much is still unknown about how synthetic cathinones affect the human brain.
    [Show full text]
  • Study of Adulterants and Diluents in Some Seized Captagon-Type Stimulants
    MedDocs Publishers ISSN: 2638-1370 Annals of Clinical Nutrition Open Access | Mini Review Study of Adulterants and Diluents in Some Seized Captagon-Type Stimulants Ali Zaid A Alshehri1,2*; Mohammed saeed Al Qahtani1,3; Mohammed Aedh Al Qahtani1,4; Abdulhadi M Faeq1,5; Jawad Aljohani1,6; Ammar AL-Farga7 1Department of Medical Laboratory Technology, College of Applied Medical Sciences, University of Jeddah, Saudi Arabia 2Poison Control and Medical Forensic Chemistry Center, Ministry of Health, Riyadh, Saudi Arabia 3Khammis Mushayte Maternity & Children Hospital, Ministry of Health, Saudi Arabia 4Ahad Rufidah General, Hospital, Aseer, Ministry of Health, Saudi Arabia 5Comprehensive Specialized Clinics of Security Forces in Jeddah, Ministry of Interior, Saudi Arabia 6Compliance Department, Yanbu Health Sector, Ministry of Health, Saudi Arabia 7Department of Biochemistry, Faculty of Science, University of Jeddah, Saudi Arabia *Corresponding Author(s): Ali Zaid A Alshehri Department of Medical Laboratory Technology, College of Applied Medical Sciences, University of Jeddah, Saudi Arabia Email: [email protected] Received: Apr 27, 2020 Accepted: Jun 05, 2020 Published Online: Jun 10, 2020 Journal: Annals of Clinical Nutrition Publisher: MedDocs Publishers LLC Online edition: http://meddocsonline.org/ Copyright: © Alshehri AZA (2020). This Article is distributed under the terms of Creative Commons Attribution 4.0 International License Introduction ATS are synthetic compounds belonging to the class of stimu- and heroin users combined [3,4]. Fenethylline, 7-(2-amethyl lants that excite the Central Nervous System (CNS) to produce phenyl-amino ethyl)-theophylline, is a theophylline derivative of adrenaline-like effects such as amphetamine, methamphet- amphetamine. It is a psychoactive drug which is similar to am- amine, fenethylline, methylphenidate and dextroamphetamine phetamine in many ways [5].
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Reviews Insights Into Pathophysiology from Medication-Induced Tremor
    Freely available online Reviews Insights into Pathophysiology from Medication-induced Tremor 1* 1 1 1 John C. Morgan , Julie A. Kurek , Jennie L. Davis & Kapil D. Sethi 1 Movement Disorders Program Parkinson’s Foundation Center of Excellence, Department of Neurology, Medical College of Georgia, Augusta, GA, USA Abstract Background: Medication-induced tremor (MIT) is common in clinical practice and there are many medications/drugs that can cause or exacerbate tremors. MIT typically occurs by enhancement of physiological tremor (EPT), but not all drugs cause tremor in this way. In this manuscript, we review how some common examples of MIT have informed us about the pathophysiology of tremor. Methods: We performed a PubMed literature search for published articles dealing with MIT and attempted to identify articles that especially dealt with the medication’s mechanism of inducing tremor. Results: There is a paucity of literature that deals with the mechanisms of MIT, with most manuscripts only describing the frequency and clinical settings where MIT is observed. That being said, MIT emanates from multiple mechanisms depending on the drug and it often takes an individualized approach to manage MIT in a given patient. Discussion: MIT has provided some insight into the mechanisms of tremors we see in clinical practice. The exact mechanism of MIT is unknown for most medications that cause tremor, but it is assumed that in most cases physiological tremor is influenced by these medications. Some medications (epinephrine) that cause EPT likely lead to tremor by peripheral mechanisms in the muscle (b-adrenergic agonists), but others may influence the central component (amitriptyline).
    [Show full text]
  • Adenosine Strongly Potentiates Pressor Responses to Nicotine in Rats (Caffeine/Blood Pressure/Sympathetic Nervous System) REID W
    Proc. Nadl. Acad. Sci. USA Vol. 81, pp. 5599-5603, September 1984 Neurobiology Adenosine strongly potentiates pressor responses to nicotine in rats (caffeine/blood pressure/sympathetic nervous system) REID W. VON BORSTEL, ANDREW A. RENSHAW, AND RICHARD J. WURTMAN Laboratory of Neuroendocrine Regulation, Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, MA 02139 Communicated by Walle J. H. Nauta, May 14, 1984 ABSTRACT Intravenous infusion of subhypotensive doses epinephrine output during nerve stimulation is decreased (6). of adenosine strongly potentiates the pressor response of anes- Adenosine can be produced ubiquitously and is present in thetized rats to nicotine. A dose of nicotine (40 jpg/kg, i.v.), plasma and cerebrospinal fluid (7, 8); the nucleoside can which, given alone, elicits a peak increase in diastolic pressure therefore potentially act at a number of different loci, both of -15 mm Hg, increases pressure by -70 mm Hg when arte- central and peripheral, within the complex neural circuitry rial plasma adenosine levels have been increased to 2 puM from involved in the regulation of a single physiological function, a basal concentration of =1 puM. The pressor response to ciga- such as maintenance of blood pressure or heart rate. Neither rette smoke applied to the lungs is also strongly potentiated normal plasma adenosine levels nor the relative and absolute during infusion of adenosine. Slightly higher adenosine con- sensitivities of neural and cellular processes to adenosine centrations (-4 jaM) attenuate pressor responses to electrical have been well characterized in intact animals. The studies stimulation of preganglionic sympathetic nerves, or to injec- described below explore the effects of controlled measured tions of the a-adrenergic agonist phenylephrine, but continue alterations in arterial plasma adenosine concentrations on to potentiate pressor responses to nicotine.
    [Show full text]
  • Neuronal Adenosine A2A Receptors Signal Ergogenic Effects of Caffeine
    www.nature.com/scientificreports OPEN Neuronal adenosine A2A receptors signal ergogenic efects of cafeine Aderbal S. Aguiar Jr1,2*, Ana Elisa Speck1,2, Paula M. Canas1 & Rodrigo A. Cunha1,3 Cafeine is one of the most used ergogenic aid for physical exercise and sports. However, its mechanism of action is still controversial. The adenosinergic hypothesis is promising due to the pharmacology of cafeine, a nonselective antagonist of adenosine A1 and A2A receptors. We now investigated A2AR as a possible ergogenic mechanism through pharmacological and genetic inactivation. Forty-two adult females (20.0 ± 0.2 g) and 40 male mice (23.9 ± 0.4 g) from a global and forebrain A2AR knockout (KO) colony ran an incremental exercise test with indirect calorimetry (V̇O2 and RER). We administered cafeine (15 mg/kg, i.p., nonselective) and SCH 58261 (1 mg/kg, i.p., selective A2AR antagonist) 15 min before the open feld and exercise tests. We also evaluated the estrous cycle and infrared temperature immediately at the end of the exercise test. Cafeine and SCH 58621 were psychostimulant. Moreover, Cafeine and SCH 58621 were ergogenic, that is, they increased V̇O2max, running power, and critical power, showing that A2AR antagonism is ergogenic. Furthermore, the ergogenic efects of cafeine were abrogated in global and forebrain A2AR KO mice, showing that the antagonism of A2AR in forebrain neurons is responsible for the ergogenic action of cafeine. Furthermore, cafeine modifed the exercising metabolism in an A2AR-dependent manner, and A2AR was paramount for exercise thermoregulation. Te natural plant alkaloid cafeine (1,3,7-trimethylxantine) is one of the most common ergogenic substances for physical activity practitioners and athletes 1–10.
    [Show full text]
  • Do You Know... Caffeine
    Do You Know... What is it? Caffeine is a stimulant that speeds up your central nervous system. It is the world’s most Caffeine popular drug. Caffeine occurs naturally in products such as coffee, tea, chocolate and cola soft drinks, and is added to a variety of prescription and over-the-counter medications, including cough, cold and pain remedies. Energy drinks may contain both naturally occurring and added caffeine. The following are typical amounts of caffeine in products you may use regularly. (A cup refers to a small take-out cup size of 237 mL [8 oz]. Keep in mind that coffee and tea are often served in much larger cups.) · cup of brewed coffee: 135 mg · cup of instant coffee: 76–106 mg · cup of decaffeinated coffee: about 3 mg · cup of tea: 43 mg · can of regular cola soft drink containing caffeine (355 ml): 36–50 mg · can of energy drink (250 ml): 80 mg · dark chocolate (28 g): 19 mg · milk chocolate (28 g): 7 mg · packet of hot chocolate mix: 7 mg · stay-awake pills: 100 mg 1/4 © 2003, 2011 CAMH | www.camh.ca To find out the amount of caffeine in headache and cold Who uses caffeine? medicines, check the label of over-the-counter medication, Caffeine is the most widely used psychoactive substance or ask your pharmacist about caffeine in prescription drugs. in the world. In North America, more than 80 per cent of adults regularly consume caffeine. The average amount In Canada, manufacturers of products that contain of caffeine consumed per person in Canada (from all naturally occurring caffeine are not required by law to sources) is estimated to be 210 to 238 mg per day.
    [Show full text]
  • Pharmaceuticals and Medical Devices Safety Information No
    Pharmaceuticals and Medical Devices Safety Information No. 296 November 2012 Executive Summary Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Office of Safety I For full text version of Pharmaceuticals and Medical Devices Safety Information (PMDSI) No. 296, interested readers are advised to consult the PMDA website for upcoming information. The contents of this month's PMDSI are outlined below. 1. Summary of Payment/Non-payment of Adverse Drug Reaction Relief Benefits and Drugs with Many Cases of Improper Use Under the Relief System for Sufferers from Adverse Drug Reactions, relief benefits have not been approved in some cases due to improper use of drugs. MHLW/PMDA presents here drugs with many cases of improper use and encourages proper use of drugs. 2. Important Safety Information Regarding the revision of the Precautions section of package inserts of drugs in accordance with the Notification dated October 30, 2012, the contents of important revisions and case summaries that served as the basis for these revisions will be provided in section 2 of the full text. 1. Imatinib Mesilate 2. Ceftriaxone Sodium Hydrate 3. Mexiletine Hydrochloride 3. Revision of Precautions (No. 241) Revisions of Precautions etc. for the following pharmaceuticals: Inactivated Poliomyelitis Vaccine, Acetaminophen, Isopropylantipyrine/Acetaminophen/Allylisopropylacetylurea/Anhydrous Caffeine, Tramadol Hydrochloride/Acetaminophen, Salicylamide/Acetaminophen/Anhydrous Caffeine/Chlorpheniramine Maleate, Diprophylline/Dihydrocodeine Phosphate/dl-Methylephedrine Hydrochloride/Diphenhydramine Salicylate/Acetaminophen/Bromovalerylurea, Spironolactone, Dabigatran Etexilate Methanesulfonate, Rotavirus Vaccine, Live, Oral, Pentavalent 4. List of Products Subject to Early Post- marketing Phase Vigilance (as of November 2012) A list of products subject to Early Post-marketing Phase Vigilance as of November 1, 2012 will be provided in section 4 of the full text.
    [Show full text]
  • Convergent Evolution of Caffeine in Plants by Co-Option of Exapted Ancestral Enzymes
    Convergent evolution of caffeine in plants by co-option of exapted ancestral enzymes Ruiqi Huanga, Andrew J. O’Donnella,1, Jessica J. Barbolinea, and Todd J. Barkmana,2 aDepartment of Biological Sciences, Western Michigan University, Kalamazoo, MI 49008 Edited by Ian T. Baldwin, Max Planck Institute for Chemical Ecology, Jena, Germany, and approved July 18, 2016 (received for review March 25, 2016) Convergent evolution is a process that has occurred throughout the the evolutionary gain of traits such as caffeine that are formed via tree of life, but the historical genetic and biochemical context a multistep pathway. First, although convergently co-opted genes, promoting the repeated independent origins of a trait is rarely such as XMT or CS, may evolve to encode enzymes for the same understood. The well-known stimulant caffeine, and its xanthine biosynthetic pathway, it is unknown what ancestral functions they alkaloid precursors, has evolved multiple times in flowering plant historically provided that allowed for their maintenance over mil- history for various roles in plant defense and pollination. We have lions of years of divergence. Second, it is unknown how multiple shown that convergent caffeine production, surprisingly, has protein components are evolutionarily assembled into an ordered, evolved by two previously unknown biochemical pathways in functional pathway like that for caffeine biosynthesis. Under the chocolate, citrus, and guaraná plants using either caffeine synthase- cumulative hypothesis (26), it is predicted that enzymes catalyzing or xanthine methyltransferase-like enzymes. However, the pathway earlier reactions of a pathway must evolve first; otherwise, enzymes and enzyme lineage used by any given plant species is not predict- that perform later reactions would have no substrates with which to able from phylogenetic relatedness alone.
    [Show full text]